About Cuorips
Cuorips is a company based in Chuo (Japan) founded in 2017. Cuorips has raised $13.18 million across 1 funding round from investors including Osaka University, JIC Venture Growth Investments and JAFCO Group. The company has 56 employees. Cuorips operates in a competitive market with competitors including Mercator MedSystems, Vesigen Therapeutics, Nectero Medical, Amarna Therapeutics and PharmaIN, among others.
- Headquarter Chuo, Japan
- Employees 56
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website cuorips.co.jp
- Legal Name Cuorips Inc.
- Annual Revenue$1.33 M (USD)21.19as on Mar 31, 2026
- Net Profit-$6.4 M (USD)-58.71as on Mar 31, 2026
- EBITDA-$6.25 M (USD)-94.09as on Mar 31, 2026
- Total Equity Funding$13.18M (USD)
in 1 rounds
- Latest Funding Round$13.18M (USD), Series A
Mar 2021
- InvestorsOsaka University
& 4 more
- Employee Count56
Funding Insights of Cuorips
Cuorips has successfully raised a total of $13.18M through 1 strategic funding round. The most recent funding activity was a Series A round of $13.18 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.18M
- Total Rounds 1
- Last Round Series A — $13.18M
- First Round $13.18M
(Mar 2021)
- Investors Count 5
All 1 funding rounds of Cuorips with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $13.18M | Series A | – | JIC Venture Growth Investments |
5 investors in total: 5 institutional.
Investors in Cuorips
Cuorips has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Osaka University, JIC Venture Growth Investments and JAFCO Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on growth stage companies | – | j-vgi.co.jp | Minato City, Japan | |
VC firm investing in Japan and the US | – | nvcc.co.jp | Chiyoda City, Japan | |
Buyouts are targeted through venture capital and private equity investments. | – | jafco.co.jp | Minato City, Japan | |
University offering multiple courses and degrees across diversified streams | 1931 | osaka-u.ac.jp | Osaka, Japan | |
A forum focused on innovation in regenerative medicine is operated. | – | firm.or.jp | Japan |
Investor details for Cuorips
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cuorips
9 people are tracked at Cuorips (3 in leadership, 6 in board & advisors); the tracked headcount is 56.
| Name | Role | Group |
|---|---|---|
Takayuki Kusanagi | CEO | Leadership |
Manabu Inoue | EVP & COO | Leadership |
Yoshiki Sawa | Director & CTO | Leadership |
Toru Sumiyoshi | Audit & Supervisory Board Member | Board & advisors |
Kotaro Yamamoto | Audit & Supervisory Board Member | Board & advisors |
Shinji Abe | Audit & Supervisory Board Member | Board & advisors |
Tadashi Samejima | Director | Board & advisors |
Ryohei Shimazaki | Director | Board & advisors |
Tetsuya Ohira | Director | Board & advisors |
Complete people profiles for Cuorips
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Cuorips
Cuorips is a publicly listed company on the TSE with ticker symbol 4894 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jun 2023
- Listed onTSE: 48940
- Listed entityCuorips Inc.
- Exchange sectorHealth technology
- ISINJP3266030000
- Share price6,310.00 JPY (+4.3% on the day) · 2026-10-09
- Market capitalisation56,037,271,862.00 JPY
- EPS (diluted, trailing year)-138.29 JPY
- Volume (last session)108,300
Financials of Cuorips
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 212.3M JPY | -1.02B JPY | -996.8M JPY |
| 2024 | 175.2M JPY | -644.3M JPY | -513.6M JPY |
| 2023 | 23.1M JPY | -632.2M JPY | -518.4M JPY |
| 2022 | 38.3M JPY | -452.1M JPY | -371.8M JPY |
| 2021 | 13.9M JPY | -375.3M JPY | -280.5M JPY |
Detailed financial statements for Cuorips
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cuorips
3 dated milestones of Cuorips across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Cuorips is founded.
- Funding First funding round of $13.2M.
- IPO Lists on the stock exchange (IPO).
Competitors of Cuorips
Cuorips operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mercator MedSystems, Vesigen Therapeutics, Nectero Medical, Amarna Therapeutics and PharmaIN, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mercatormed.com | 2000 | San Leandro, United States | $31.8M | – | Catheter-guided microfluid injection systems are developed for targeted tissue therapies. | |
| vesigen.com | 2019 | Cambridge, United States | $28.5M | 27 | Non-viral delivery platform for intracellular therapeutics using ARMMs technology | |
| necteromedical.com | 2019 | Bethlehem, United States | $115.5M | 6 | An endovascular device for treating abdominal aortic aneurysms is developed. | |
| amarnatherapeutics.com | 2008 | Leiden, Netherlands | $11.02M | – | Viral gene delivery vectors are developed for diverse diseases. | |
| pharmain.com | 2001 | Bothell, United States | $1.5M | – | Proprietary drug delivery platforms are developed for API enhancement. | |
| acmbiolabs.com | 2012 | Singapore | – | – | Artificial membrane platforms are utilized for vaccine and antibody production. | |
| advancednanotherapies.com | 2018 | Los Gatos, United States | $26.38M | – | Developer of a drug delivery device for cardiac vascular diseases | |
| samyangbiopharm.com | 2011 | Seoul, South Korea | – | – | Transdermal drug patches and wound closure devices are developed. | |
| clavispharma.com | 2001 | Oslo, Norway | – | – | Develops innovative small molecule therapeutics for cancer treatment. |
Detailed competitors of Cuorips
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cuorips
The website of Cuorips (cuorips.co.jp) receives about 3.7K visits a month.
- Monthly visits3.7K
▲ 11.9% vs previous month
Websites whose visitors overlap most with Cuorips. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
finance.yahoo.co.jp | finance.yahoo.co.jp | 100% | – | #530 | – |
| sbisec.co.jp | 88% | – | – | View details | |
asset-alive.com | asset-alive.com | 83% | – | #472,977 | – |
Latest news on Cuorips
Complete news archive for Cuorips
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cuorips
10 companies that operate in the same segment as Cuorips (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cuorips
Cuorips was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Cuorips is headquartered in Chuo, Japan. It is registered at Chuo, Yamanashi Prefecture, Japan.
Takayuki Kusanagi is the current CEO of Cuorips.
Cuorips is a funded company, having raised a total of $13.18M across 1 funding round to date. The company's 1st funding round was a Series A of $13.18M, raised on Mar 2021.
Cuorips has 56 employees.
Annual revenue of Cuorips is $1.33M as on Mar 31, 2026.
Cuorips was founded in 2017 in Chuo City, Japan, within the biotechnology sector focused on cardiovascular treatments. A proprietary drug delivery platform for heart failure is developed by the company. iPS cell-derived cardiomyocyte sheets form the core of this platform, which are cultivated and then grafted onto affected hearts to support improved cardiac function. Operations center on advancing this regenerative approach for clinical application.
Cuorips's top competitors include Mercator MedSystems, Vesigen Therapeutics and PharmaIN.
Yes, Cuorips is publicly traded on TSE under the ticker symbol 4894.
Cuorips has 5 investors. Key investors include Osaka University, JIC Venture Growth Investments, JAFCO Group, Forum for Innovative Regenerative Medicine, and Nippon Venture Capital.